About Eupraxia Pharmaceuticals Inc. Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address ...
The decision to use b/tsDMARD monotherapy vs combination therapy with MTX when treating PsA is primarily based on patient satisfaction and drug tolerability.
FORT-2 is a phase 1b/2 non-randomized clinical trial conducted in 30 centers across Asia, Europe and North America. It is the first clinical trial to evaluate the safety, tolerability and the ...